login
  Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page
 

Angel Catheter is CE-marked


Monday, 21 May 2012 10:07
Angel Catheter
Angel Catheter

BiO2 Medical has announced that it has received CE mark approval for the Angel Catheter, a nitinol inferior vena cava (IVC) filter, permanently attached to a central venous catheter (CVC) for the use of preventing pulmonary embolism in critically ill patients with venous thromboembolism for whom anticoagulation therapy is temporarily contraindicated. 


According to a company release, the Angel device is the first IVC filter with a prophylactic use indication, and allows attending physicians the ability to place an IVC filter bedside in the intensive care unit, in a procedure resembling a routine CVC placement procedure.

“Obtaining the CE clearance for commercialisation of the Angel catheter in Europe is a significant step in our goal to provide an alternative for critically ill patients at high risk of pulmonary embolism. It also validates a long and complex process of extensive testing for the use of our device as a prophylaxis against pulmonary embolism,” said Luis F Angel, chief medical officer, BiO2 Medical, and inventor of the Angel catheter.




Add New Comment

Most popular


First drug-eluting balloon approved in USA
Friday, 10 Oct 2014
The FDA has approved the Lutonix drug-eluting balloon for the management of peripheral artery disease. This is the first time that the agency has approved such a device for this indication in the USA. First drug-eluting balloon approved in USA

Bioresorbable scaffolds can produce comparable acute results to metal stents
Tuesday, 04 Nov 2014
Speaking at the Asian Society for Vascular Surgery meeting (5–7 September, Hong Kong, China), Andrew Holden commented that studies indicate that bioresorbable scaffolds can produce comparable acute ... Bioresorbable scaffolds can produce comparable acute results to metal stents

Live from VEITH 2014: SUPERB results show 94% freedom from reintervention with nominal deployment of Supera at three years
Wednesday, 19 Nov 2014
Three-year follow-up results of patients treated with the Supera stent show that nominal deployment or slight compression of the device delivers the best outcomes in terms of durability, and that ... Live from VEITH 2014: SUPERB results show 94% freedom from reintervention with nominal deployment of Supera at three years

Features


A new classification system for acute type B aortic dissection predicting reverse aortic remodelling
Wednesday, 19 Nov 2014
In recent years, primary stent grafting for complicated type B aortic dissection has been applied with favourable results. Thoracic aortic endovascular repair can be offered with a relatively low ... A new classification system for acute type B aortic dissection predicting reverse aortic remodelling

Resolving differences between carotid stenosis management guidelines
Wednesday, 19 Nov 2014
Anne Abbott, Melbroune, Australia, writes that while some variability in guideline recommendations is due to different publication dates, much is due to bias in what evidence is considered and how it ... Resolving differences between carotid stenosis management guidelines

Profiles


Martin Björck
Wednesday, 01 Oct 2014
Martin Björck, Uppsala University Hospital, Sweden, holds the only professor-chair of vascular ... Martin Björck

Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions